ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
128.508,67
1,09%
S&P 500
5.127,79
1,26%
US Dollar vs BRL
5,0726
0,00%
Bitcoin
65.203,95
1,88%
Brent Oil
83,42
0,35%
Registration Strip Icon for tools Aumente o nível de sua negociação com nossas ferramentas poderosas e insights em tempo real, tudo em um só lugar.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. Reino Unido
  5. LSE
  6. Roche Holding Ag (0QQ6)

  7. Roche Holding Ag (0QQ6) Notícias

0QQ6 Roche Holding Ag

229,20
0,00 (0,00%)
02 Mai 2024 - Fechado
Atrasado em 15 minutos
Nome da Ação Código da Ação Bolsa de Valores Tipo de Ativo
Roche Holding Ag 0QQ6 Londres Ordinária
  Variação do Dia (p) Variação do Dia % Último Preço Hora
Upgrade Icon
0,00 0,00% 229,20 21:00:00
Preço de Abertura Preço Mínimo Preço Máximo Fech. Hoje Fech. Anterior
229,20 229,20
mais cotações »

Notícias Recentes

Data Hora Fonte Título
16/01/202403:00GLOBEEuropean Commission approves Roche’s Tecentriq SC, the EU's..
29/12/202318:30GLOBERoche enters into a definitive agreement to acquire..
19/12/202311:40GLOBEFDA grants priority review to Xolair (omalizumab) for..
15/12/202303:15GLOBERoche named among top three most sustainable healthcare..
11/12/202303:00GLOBENew data for Roche’s Columvi and Lunsumio presented at ASH..
09/12/202313:30GLOBENew data reinforce the benefit of early preventative..
08/12/202313:50GLOBERoche's Kadcyla is the first targeted therapy to show..
08/12/202313:45GLOBERoche’s inavolisib combination reduces the risk of disease..
05/12/202303:00GLOBERoche announces positive Phase III results for inavolisib..
04/12/202303:00GLOBERoche enters into a definitive merger agreement to acquire..
27/11/202303:00GLOBERoche expands hepatitis diagnostics portfolio to help..
16/11/202303:00GLOBERoche launches automated serology hepatitis E virus tests,..
14/11/202303:00GLOBERoche’s subcutaneous injection of Tecentriq recommended by..
09/11/202303:00GLOBERoche’s Elecsys NfL test, an important aid for those living..
30/10/202317:01GLOBE[Ad hoc announcement pursuant to Art. 53 LR] Roche announces..
27/10/202302:00GLOBE[Ad hoc announcement pursuant to Art. 53 LR] FDA approves..
23/10/202308:18IHMARKETNEWSMonday’s Wall Street Highlights: Philips, Chevron,..
23/10/202302:00GLOBE[Ad hoc announcement pursuant to Art. 53 LR] Roche enters..
19/10/202302:00GLOBE[Ad hoc-Mitteilung gemäss Art. 53 KR] Roche mit gutem..
18/10/202302:03GLOBERoche IL-6 is the first immunoassay approved to aid sepsis..
18/10/202302:00GLOBERoche’s Alecensa reduces the risk of disease recurrence or..
13/10/202310:30GLOBELate-breaking data for Roche’s BTK inhibitor fenebrutinib..
12/10/202302:00GLOBENew data for Roche’s OCREVUS show that after 10 years of..
11/10/202303:00GLOBERoche’s OCREVUS twice-yearly, 10-minute subcutaneous..
10/10/202302:00GLOBERoche’s Vabysmo maintained vision improvements with extended..
04/10/202302:00GLOBEMajority of newborn babies with spinal muscular atrophy..
02/10/202302:00GLOBERoche to present new key clinical and real-world data at..
07/09/202308:00GLOBERoche and Alnylam report positive topline results from Phase..
01/09/202302:00GLOBERoche’s Alecensa delivers unprecedented Phase III results..
29/08/202306:00GLOBERoche’s Tecentriq becomes the first subcutaneous..
29/08/202302:00GLOBEEuropean Commission approves Roche’s Evrysdi for babies..
23/08/202302:22GLOBE[Ad hoc announcement pursuant to Art. 53 LR] Roche provides..
27/07/202302:00GLOBE[Ad hoc-Mitteilung gemäss Art. 53 KR] Roche verzeichnet..
24/07/202302:00GLOBERoche enters partnership with Alnylam to co-develop and..
21/07/202310:30GLOBECHMP recommends Roche’s Evrysdi for babies under two months..
20/07/202302:00GLOBENew clinical and real-world data for Roche’s Vabysmo at ASRS..
13/07/202302:00GLOBEPositive Phase III results for Roche’s OCREVUS (ocrelizumab)..
11/07/202302:00GLOBEEuropean Commission approves Roche’s fixed-duration Columvi..
30/06/202312:50GLOBEFour-year follow up data for Roche’s Evrysdi show continued..
16/06/202302:00GLOBEFDA approves Roche’s Columvi, the first and only bispecific..
13/06/202302:00GLOBERoche awarded WHO prequalification for the cobas® HPV test,..
09/06/202309:45GLOBENew data show Roche’s subcutaneously administered crovalimab..
17/05/202302:00GLOBERoche’s BTK inhibitor fenebrutinib significantly reduced..
09/05/202302:00GLOBEFDA accepts application for Roche’s Vabysmo for the..

Seu Histórico Recente

LSE
0QQ6
Roche
Delayed Upgrade Clock
ADVFN Logo

Brasil
Empresa
Negócios
Popular
Obter o aplicativo

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados